Efficacy of carrellizumab combined with hepatic arterial chemoembolization in the treatment of primary liver cancer and its effect on T lymphocyte subsets,tumor markers levels
Objective To investigate the efficacy of carrellizumab combined with hepatic arterial chemoembolization(TACE)in the treatment of primary liver cancer(PLC)and its effect on T lymphocyte subsets,tumor markers levels.Methods Middle-aged and advanced PLC patients admitted to the Pingmei Shenma Medical Group General Hospital from January 2020 to May 2022 were selected and divided into a control group and an observation group by random number table method.The control group was given TACE treatment,and the observation group was given carrilizumab combined with TACE treatment.The short-term efficacy,T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),tumor markers[cytokeratin 19(CK19),alpha-fetoprotein(AFP)],and adverse reactions were compared between the two groups.Results A total of 86 PLC patients were included,43 cases in the control group and 43 cases in the observation group.The objective response rate(ORR)and disease control rate(DCR)in observation group were 65.12%and 93.02%,respectively,which was higher than 41.86%and 72.09%in the control group(P<0.05).At 1 month and 3 months after treatment,the levels of CD3+,CD4+,CD4+/CD8+ in peripheral blood of the observation group were higher than those of the control group(P<0.05).Serum CK19 and AFP levels in the observation group were lower than those in the control group at 1 month and 3 months after treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Carrellizum-ab combined with TACE in the treatment of middle and late PLC can significantly improve the short-term efficacy,and its mechanism of action is related to the improvement of T lymphocyte subsets,the downregulation of serum CK19 and AFP levels without increased incidence of adverse reactions.
NETL
NSTL
万方数据
